|
1
|
Campo E and Rule S: Mantle cell lymphoma:
Evolving management strategies. Blood. 125:48–55. 2015. View Article : Google Scholar
|
|
2
|
Chen Y, Wang M and Romaguera J: Current
regimens and novel agents for mantle cell lymphoma. Br J Haematol.
167:3–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ghielmini M and Zucca E: How I treat
mantle cell lymphoma. Blood. 114:1469–1476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chapoval AI, Ni J, Lau JS, Wilcox RA,
Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al: B7-H3: A
costimulatory molecule for T cell activation and IFN-gamma
production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steinberger P, Majdic O, Derdak SV,
Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF,
Stöckl J and Knapp W: Molecular characterization of human
4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J
Immunol. 172:2352–2359. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu H, Cheung IY, Guo HF and Cheung NK:
MicroRNA miR-29 modulates expression of immunoinhibitory molecule
B7-H3: Potential implications for immune based therapy of human
solid tumors. Cancer Res. 69:6275–6281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen C, Shen Y, Qu QX, Chen XQ, Zhang XG
and Huang JA: Induced expression of B7-H3 on the lung cancer cells
and macrophages suppresses T-cell mediating anti-tumor immune
response. Exp Cell Res. 319:96–102. 2013. View Article : Google Scholar
|
|
8
|
Yamato I, Sho M, Nomi T, Akahori T,
Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H and Nakajima Y:
Clinical importance of B7-H3 expression in human pancreatic cancer.
Br J Cancer. 101:1709–1716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ingebrigtsen VA, Boye K, Tekle C, Nesland
JM, Flatmark K and Fodstad O: B7-H3 expression in colorectal
cancer: Nuclear localization strongly predicts poor outcome in
colon cancer. Int J Cancer. 131:2528–2536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun TW, Gao Q, Qiu SJ, Zhou J, Wang XY, Yi
Y, Shi JY, Xu YF, Shi YH, Song K, et al: B7-H3 is expressed in
human hepatocellular carcinoma and is associated with tumor
aggressiveness and postoperative recurrence. Cancer Immunol
Immunother. 61:2171–2182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arigami T, Narita N, Mizuno R, Nguyen L,
Ye X, Chung A, Giuliano AE and Hoon DS: B7-h3 ligand expression by
primary breast cancer and associated with regional nodal
metastasis. Ann Surg. 252:1044–1051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu Y, Lv X, Wu Y, Xu J, Wang L, Chen W,
Zhang W, Li J, Zhang S and Qiu H: Expression of costimulatory
molecule B7-H3 and its prognostic implications in human acute
leukemia. Hematology. Aug 16–2014.(Epub ahead of print). PubMed/NCBI
|
|
13
|
Zhao D, Lin L, Ge Q, et al: Relation of
B7-H3 molecule expression in multiple myeloma with poor prognosis
and bone destruction. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
21:637–642. 2013.(In Chinese). PubMed/NCBI
|
|
14
|
Wilcox RA, Ansell SM, Lim MS, Zou W and
Chen L: The B7 homologues and their receptors in hematologic
malignancies. Eur J Haematol. 88:465–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo L, Chapoval AI, Flies DB, Zhu G,
Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, et al: B7-H3
enhances tumor immunity in vivo by costimulating rapid clonal
expansion of antigen-specific CD8+ cytolytic T cells. J
Immunol. 173:5445–5450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Vale M, Leung E, Kanwar JR, Gupta R
and Krissansen GW: Mouse B7-H3 induces antitumor immunity. Gene
Ther. 10:1728–1734. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brunner A, Hinterholzer S, Riss P, Heinze
G and Brustmann H: Immunoexpression of B7-H3 in endometrial cancer:
Relation to tumor T-cell infiltration and prognosis. Gynecol Oncol.
124:105–111. 2012. View Article : Google Scholar
|
|
18
|
Leitner J, Klauser C, Pickl WF, Stöckl J,
Majdic O, Bardet AF, Kreil DP, Dong C, Yamazaki T, Zlabinger G, et
al: B7-H3 is a potent inhibitor of human T-cell activation: No
evidence for B7-H3 and TREML2 interaction. Eur J Immunol.
39:1754–1764. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suh WK, Gajewska BU, Okada H, Gronski MA,
Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, et
al: The B7 family member B7-H3 preferentially down-regulates T
helper type 1-mediated immune responses. Nat Immunol. 4:899–906.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tekle C, Nygren MK, Chen YW, Dybsjord I,
Nesland JM, Maelandsmo GM and Fodstad O: B7-H3 contributes to the
metastatic capacity of melanoma cells by modulation of known
metastasis-associated genes. Int J Cancer. 130:2282–2290. 2012.
View Article : Google Scholar
|
|
21
|
Chen YW, Tekle C and Fodstad O: The
immunoregulatory protein human B7H3 is a tumor-associated antigen
that regulates tumor cell migration and invasion. Curr Cancer Drug
Targets. 8:404–413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lemke D, Pfenning PN, Sahm F, Klein AC,
Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M, et
al: Costimulatory protein 4IgB7H3 drives the malignant phenotype of
glioblastoma by mediating immune escape and invasiveness. Clin
Cancer Res. 18:105–117. 2012. View Article : Google Scholar
|
|
23
|
Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong
F, Zhang ZX, Zhang GB, Zhang XG and Zhao H: B7-H3 overexpression in
pancreatic cancer promotes tumor progression. Int J Mol Med.
31:283–291. 2013.
|
|
24
|
Yuan H, Wei X, Zhang G, Li C, Zhang X and
Hou J: B7-H3 over expression in prostate cancer promotes tumor cell
progression. J Urol. 186:1093–1099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Zhang Q, Chen W, Shan B, Ding Y,
Zhang G, Cao N, Liu L and Zhang Y: B7-H3 is overexpressed in
patients suffering osteosarcoma and associated with tumor
aggressiveness and metastasis. PLoS One. 8:e706892013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu H, Tekle C, Chen YW, Kristian A, Zhao
Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, et al: B7-H3
silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3
phosphorylation. Mol Cancer Ther. 10:960–971. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao X, Zhang GB, Gan WJ, Xiong F, Li Z,
Zhao H, Zhu DM, Zhang B, Zhang XG and Li DC: Silencing of B7-H3
increases gemcitabine sensitivity by promoting apoptosis in
pancreatic carcinoma. Oncol Lett. 5:805–812. 2013.PubMed/NCBI
|
|
28
|
Li Y, Wang J, Li C and Ke XY: Contribution
of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting
therapy. Leuk Lymphoma. 53:2015–2023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rummel MJ, Niederle N, Maschmeyer G, Banat
GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M,
Balser C, et al; Study group indolent Lymphomas (StiL).
Bendamustine plus rituximab versus CHOP plus rituximab as
first-line treatment for patients with indolent and mantle-cell
lymphomas: An open-label, multicentre, randomised, phase 3
non-inferiority trial. Lancet. 381:1203–1210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Chong KK, Nakamura Y, Nguyen L,
Huang SK, Kuo C, Zhang W, Yu H, Morton DL and Hoon DS: B7-H3
associated with tumor progression and epigenetic regulatory
activity in cutaneous melanoma. J Invest Dermatol. 133:2050–2058.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R,
Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell
lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shapiro SD: Matrix metalloproteinase
degradation of extracellular matrix: Biological consequences. Curr
Opin Cell Biol. 10:602–608. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mussetti A, Kumar A, Dahi PB, Perales MA
and Sauter CS: Lifting the mantle: Unveiling new treatment
approaches in relapsed or refractory mantle cell lymphoma. Blood.
Nov 1–2014.(Epub ahead of print). pii: S0268-960X(14)00083-6.
View Article : Google Scholar
|
|
34
|
Gil L, Kazmierczak M, Kroll-Balcerzak R
and Komarnicki M: Bendamustine-based therapy as first-line
treatment for non-Hodgkin lymphoma. Med Oncol. 31:9442014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Loo D, Alderson RF, Chen FZ, Huang L,
Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, et al:
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with
potent antitumor activity. Clin Cancer Res. 18:3834–3845. 2012.
View Article : Google Scholar : PubMed/NCBI
|
